Company intelligence / Profile preview

GenEditBio

Hong Kong, New Territories, Chinageneditbio.com ↗

Ownership: Private
Employees: ~150
Development stage: Preclinical

Overview

GenEditBio is developing precision gene editing technologies and is advancing toward clinical studies. The company recently secured strategic investment from Gobi Partners GBA to accelerate their research and development efforts.

Therapeutic areas: Rare Diseases
Modalities: Gene editingGene therapyCRISPR-based therapies
Industry: Biotech

Drug pipeline

3 assets

TGFBI gene therapy

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on GenEditBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenEditBio.

Explore the full profile